Health Care Services

CVS Health is expanding its pharmacy-focused format by opening nearly 20 smaller neighborhood locations across the United States in 2026, including a new Roxbury site in the Boston area. The expansion comes as recent headlines have sent mixed signals for investors, with Medicare Advantage star rating setbacks and a legal probe weighing on sentiment, while an extended Cardinal Health distribution deal and a reaffirmed dividend provide a steadier backdrop. Even after a one-day share price decline of 1.87% and a 30-day share price return down 8.98%, the year-to-date share price return of 7.53% and a one-year total shareholder return of 14.11% indicate that longer term holders have still seen gains as shorter term momentum has faded. On the most followed view, CVS Health screens as undervalued, with a fair value of $124 against a last close of $86.16. The company has raised full-year guidance twice through the first half of 2026, Aetna's medical benefit ratio has improved, cash flow is running well ahead of plan, and all three operating segments are growing, though the story could break if Aetna's medical cost trend runs hotter than expected or if pharmacy benefit reforms compress Health Services earnings faster than planned.

Schneider Electric SE agreed to acquire U.S.-based engineering software developer PTC Inc. for $22.6 billion, or €20.1 billion, paying $205 per share in an all-cash deal. The transaction was among a string of major deals reported across sectors this week. Viatris said it will acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, while CD&R and McKesson agreed to acquire Option Care Health for $32.05 per share, valuing it at approximately $5.8 billion including debt, sending its shares up 34% in early trading Tuesday. Energy Transfer agreed to acquire Vaquero Midstream in a $2.625 billion deal consisting of $1.95 billion in cash and about 33.3 million newly issued Energy Transfer common units, and Cenovus Energy agreed to acquire Athabasca Oil in a cash-and-stock deal valued at about C$5.7 billion, a 14% premium to Athabasca's 20-day volume-weighted average trading price. Canadian utilities Emera and Canadian Utilities agreed to an all-stock merger worth C$14.3 billion, or US$10 billion, creating a combined company with a C$72 billion enterprise value and a regulated rate base of C$45 billion serving roughly 6 million customers. Separately, TKO LLC proposed to acquire Service Properties Trust's entire hospitality portfolio for $2.0 billion, and CCC Intelligent Solutions soared 13% in after-hours trading on a report that GTCR and Elliott Investment Management are in advanced discussions to purchase the car-insurance software firm.

CVS Health opened its first pharmacy-focused CVS Pharmacy in the Boston area in early October 2026 and outlined plans for nearly 20 smaller neighborhood pharmacies nationwide in 2026, part of a broader realignment of its retail footprint that also includes store-in-store locations and clinics. At the same time, the company's Aetna unit is contending with updated Medicare Advantage star ratings that affect quality bonus eligibility, a reset the article describes as material for near-term earnings sensitivity. The new Boston-area pharmacy and the nearly 20 planned sites tie directly into CVS Health's push to reinforce core pharmacy economics and care access, alongside an extended Cardinal Health distribution agreement through 2032 and ongoing store-in-store expansion. The article's narrative projects $458.7 billion in revenue and $11.3 billion in earnings by 2029, requiring 3.6% yearly revenue growth and a $6.4 billion earnings increase from $4.9 billion today, and yields a $116.28 fair value representing 35% upside to the current price. Five members of the Simply Wall St Community see CVS Health's fair value between US$104.01 and US$273.65.

Jim Cramer used the October 6 episode of Mad Money to argue that CVS Health Corporation has become too cheap to ignore after its stock plunged from $110 to $86, even as the company's earnings outlook improved. CVS reported second-quarter revenue of $106.1 billion, up 7.3% year over year, with adjusted EPS rising to $2.58 from $1.81 and GAAP diluted EPS climbing to $2.31 from $0.80, while the insurance business's medical benefit ratio improved to 87.4% from 89.9%. The company raised its full-year adjusted EPS guidance to $7.90 to $8.10 and its operating cash flow outlook to at least $11.5 billion, and management placed a reasonable floor under 2027 adjusted EPS at $8.44. Cramer said a possible 5% hit to next year's earnings should not send a stock down 22%, knocking nearly $30 billion off the company's market cap, especially not when CVS remains very strong. The uncertainty centers on Caremark, where the Centers for Medicare & Medicaid Services' July proposal would pay average sales price minus 33.4% for drugs acquired through the 340B program, and where the FTC's July settlement would separate manufacturer fees from drug list prices and add transparency and options to move away from rebate guarantees and spread pricing. CVS also said Caremark membership would decline in 2027 as contracts change and some insurance clients withdraw from markets. Using the October 7 closing price of $87.95 and the $8 midpoint of CVS's 2026 adjusted EPS guidance, the stock trades at approximately 11x this year's projected adjusted earnings, versus approximately 9.1x for Cigna based on its $278.51 closing price and its 2026 adjusted earnings guidance floor of $30.45. According to Insider Monkey's data, 88 hedge funds held CVS Health in the second quarter, compared with 84 in the first quarter, with Pzena Investment Management the most prominent shareholder at around 11.77 million shares and GQG Partners increasing its holdings by 25137% to 7.955 million shares, while short interest stood at 1.27% of the public float.

CRYO-CELL International reported fiscal third-quarter 2026 GAAP earnings per share of $0.16, beating estimates by $0.13. Revenue came in at $7.82 million, down 0.1% year over year, but still ahead of expectations by $0.37 million. Shares of the cord blood banking company rose 4.56% following the release. The results were announced in a company press release.

Alignment Health Plan said it will expand into Kern, Kings and Tulare counties and add Hoag and Astrana Health to its California Medicare Advantage provider network from 2027, widening its reach to 25 counties covering more than 6.3 million Medicare beneficiaries. At the same time, the company's largest California HMO contract was downgraded to 3.5 stars in the 2027 Medicare Star Ratings, raising questions about future quality bonus payments. Alignment is disputing the 3.5 star rating on its main California HMO contract through an appeal and legal challenge. The company's narrative projects $9.1 billion in revenue and $200.0 million in earnings by 2029, requiring 25.9% yearly revenue growth and a $159.3 million earnings increase from $40.7 million today. Before the news, the most optimistic analysts assumed revenue growth of about 27.6% a year and earnings of roughly US$247.9 million by 2029, a view that depends heavily on sustained quality metrics the new rating calls into question.

McKesson Corporation is partnering with private equity firm Clayton, Dubilier & Rice to acquire Option Care Health, Inc. for $5.8 billion including debt, taking the infusion-services provider private at $32.05 per share, a 37% premium to its previous closing price. Under the structure announced on October 6, CD&R will own 51% of the business while McKesson will hold 49% and retain the right to acquire its partner's stake in the future. The deal extends McKesson's push beyond traditional pharmaceutical distribution into higher-value specialty services, following its previously announced $2.25 billion agreement to acquire Precision Medicine Group. Option Care, which served more than 315,000 patients last year through home-based services and 184 care centers, reported second-quarter revenue up 1.9% to $1.44 billion and adjusted EBITDA up 3% to $117.5 million, and withdrew its 2026 guidance of $5.675 billion to $5.775 billion in revenue following the announcement. Analysts at Barrington and William Blair both downgraded Option Care to Market Perform, calling the $32.05-per-share offer attractive and a competing bid unlikely, while Morgan Stanley maintained an Overweight rating and a $977 price target on McKesson.

Option Care Health has agreed to a US$5.8 billion buyout from McKesson and Clayton Dubilier & Rice at US$32.05 per share in cash, sending the stock up 37.5% over the past week. The shares now trade near the deal level at about 22.2 times earnings, below the broader healthcare sector at roughly 24.7 times and the peer group average near 43.7 times. Community views on Option Care Health split between a bull case calling the stock 19% undervalued on home-infusion growth and a bear case calling it 9% overvalued after the company cut its 2026 revenue guidance to a range of US$5.675 billion to US$5.775 billion, citing a roughly 600 basis point revenue growth headwind from chronic inflammatory disease therapies.

Clover Health Investments announced that the Centers for Medicare & Medicaid Services awarded its PPO Medicare Advantage plans a 5 Star rating and its HMO Medicare Advantage plan a 4.5 Star rating for 2027, affecting payment year 2028. The 5 Star rating means Clover's PPO plans can enroll beneficiaries year round, and the company said it grew Medicare Advantage membership roughly 48% year-over-year through the first half of 2026 to more than 157,000 members, with about 98% enrolled in its wide-network PPO plans. CMS calculated the PPO rating by removing the 20 measures at issue in Clover Insurance Company v. Department of Health & Human Services, a May 27, 2026 decision now on appeal; with those measures included, the PPO plans would have received 4.5 Stars. Clover also reported a HEDIS score of 4.82 out of 5 Stars for the third straight year, ranking first among non-SNP PPO plans with over 2,000 members, unchanged under either CMS methodology. CEO Andrew Toy said the rating strengthens Clover's ability to support members and provide market-leading plans, while Medicare Advantage CEO Jamie Reynoso said the company can reinvest in more competitive benefits.

Alignment Healthcare, Inc. announced that six of its seven Medicare Advantage contracts eligible for rating earned 4 Stars or higher in the Centers for Medicare & Medicaid Services' 2027 Star Ratings, including three plans that achieved an overall 4.5-Star Rating. The high-performing contracts span Arizona, California, Nevada, North Carolina and Texas. The company also reported that its California H3815 HMO contract received a 3.5-Star Rating for 2027, a result Alignment says does not accurately reflect the contract's longstanding performance on evidence-based measures of quality, clinical outcomes and member experience. Dawn Maroney, president of Alignment Health and CEO of Alignment Health Plan, said the current Star Ratings framework has drifted too far from accurate quality measurement, and that the company intends to pursue all available administrative remedies and to litigate the measures and methodologies it believes warrant review. Maroney added that Alignment remains confident in its ability to return the California HMO contract to at least a 4-Star Rating. The 2027 Star Ratings were published by CMS on Oct. 8, 2026, with plan enrollment as of September 2026.

Guardant Health announced that Guardant360 CDx has received CE-marking under Europe's In Vitro Diagnostic Medical Devices Regulation as a companion diagnostic for AstraZeneca's ETCAMAH, also known as camizestrant, in advanced ER-positive breast cancer. The test identifies patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from the next-generation oral selective estrogen receptor degrader and complete ER antagonist. Using a simple blood draw, clinicians can test for ESR1 mutations ahead of disease progression, and the European approval follows prior regulatory approvals of Guardant360 CDx as a companion diagnostic for ETCAMAH in the United States and Japan. The clearance marks the third companion diagnostic approval for ETCAMAH and the 31st companion diagnostic approval for Guardant Health. Chairman and co-CEO Helmy Eltoukhy said the company sees tremendous potential for this testing protocol to transform the treatment of other cancer types.

RadNet posted the strongest quarter among the five testing and diagnostics services stocks tracked, reporting revenues of $622.7 million, up 25% year on year and 2.3% above analysts' expectations, with a beat on EPS estimates. Dr. Howard Berger, President and Chief Executive Officer of RadNet, said the Imaging Center and Digital Health reportable operating segments continued to demonstrate strong growth and achieve record quarterly results, with Total Company Revenue up 25.0% and Digital Health segment Revenue up 56.5% from last year's same quarter. As a group, the five testing and diagnostics services stocks tracked beat analysts' consensus estimates by 2.8%, and their share prices are up 7.2% on average since the latest earnings results. Quest Diagnostics reported revenues of $3.04 billion, up 10.2% year on year and 2.3% above expectations, while Guardant Health reported revenues of $335 million, up 44.3% year on year and 6.4% above expectations, scoring the biggest analyst estimate beat, fastest revenue growth, and highest full-year guidance raise of the whole group. Labcorp delivered the weakest performance against analyst estimates, slowest revenue growth, and weakest full-year guidance update among its peers, with revenues of $3.73 billion, up 5.8% year on year and in line with analysts' expectations, while NeoGenomics reported revenues of $201.7 million, up 11.2% year on year and 2.2% above expectations.

CVS Health has extended its long-term pharmaceutical distribution agreements with Cardinal Health and McKesson through 2032. The renewed contracts keep CVS Health as a major customer for both wholesalers, supporting its nationwide pharmacy and retail operations. Management said the agreements cover prescription drug distribution across CVS Health's retail pharmacies and other dispensing channels. The company said the extension lines up with its focus on more predictable pharmacy and PBM economics, supporting its shift toward cost-based reimbursement models such as CVS CostVantage and its goal of earning a fair margin on every script. It also underpins newer pharmacy-focused outlets opening in 2026 by helping secure supply for those smaller locations. The unresolved piece, the company said, is how pharmacy volume and profitability will track against membership trends and 340B pressure, with the next few quarterly updates through 2027 serving as a checkpoint on script counts, Caremark client retention and management's commentary on 340B headwinds.

Option Care Health has agreed to be acquired by CD&R and McKesson for $32.05 per share in cash, sending OPCH shares 32.7% higher to close at $31. The offer represents a roughly 37% premium to Option Care Health's October 5, 2026 closing price and values the company at approximately $5.8 billion in enterprise value. The deal underscores the strategic appeal of Option Care's home and alternate-site infusion care platform and reduces near-term uncertainty around its standalone outlook. Ahead of its upcoming report, Option Care is expected to post quarterly earnings of $0.48 per share, up 6.7% year over year, on revenues of $1.47 billion, up 2.4% from the year-ago quarter, with the consensus EPS estimate unchanged over the last 30 days. The stock currently carries a Zacks Rank #2 (Buy).

Option Care Health Inc. has agreed to be acquired by Clayson, Dubilier, & Rice LLC and McKesson Corp. for $5.8 billion, sending its shares up as much as 33 percent to $31.11 on Tuesday. The definitive agreement values the infusion therapy provider at $32.05 per share, a 37 percent premium over its closing price of $23.37 on Monday before the announcement. CD&R will serve as controlling shareholder with 51 percent ownership, while McKesson will hold the remaining 49 percent. The transaction is expected to close in the first half of 2027, subject to customary closing conditions including approval by Option Care Health shareholders, after which the company will cease trading on the Nasdaq exchange. Option Care Health has cancelled its live conference call and withdrawn its previously disclosed financial guidance, which had projected low to mid single digit sequential revenue growth and mid-single-digit growth in adjusted EBITDA.

NeoGenomics, Inc. issued preliminary third-quarter 2026 revenue guidance of about US$209 million with very strong next-generation sequencing growth and outlined plans to increase its full-year revenue guidance. The company also amended its bylaws to expand its Board to up to eleven directors. In a planned leadership transition, President and COO Warren Stone will become CEO and join the Board in January 2027, while current CEO Tony Zook moves to Executive Chair and the Board refreshes its independent leadership. The stronger revenue outlook, particularly in NGS, supports the near-term revenue catalyst but does not materially change the central risk that high fixed costs and heavy investment could weigh on margins if volumes soften or funding pressures persist. NeoGenomics' narrative projects $997.4 million revenue and $64.1 million earnings by 2029, with a $19.72 fair value estimate.

Google and Constellation Energy announced a 20-year deal to bring 890 MW of new nuclear capacity onto the PJM grid in Illinois, Pennsylvania and New Jersey, with Constellation spending more than $4.3 billion on the build-out. The deal follows Amazon's similar agreement with Constellation, as surging electricity demand from AI revives interest in nuclear power. Separately, Option Care Health shares jumped after the Financial Times reported that McKesson and private equity firm Clayton Dubilier & Rice are closing in on a deal to buy the medical infusion provider for $32.50 a share, or a total enterprise value of about $5.8 billion including debt, representing a 37% premium to the prior close. Under the deal, CD&R would hold a 51% majority interest and McKesson would invest $1.4 billion for a 49% stake, with Option Care remaining a separate company led by its own management. SpaceX shares were the most actively traded in the premarket as NASA nears announcing a bulk purchase of rocket launches to fuel its $30 billion drive to build a permanent base on the moon.

CD&R and McKesson have agreed to acquire Option Care Health for $32.05 per share, valuing the company at approximately $5.8 billion including debt, sending OPCH shares up 34% in early trading on Tuesday. Under the definitive agreement, CD&R will take a majority stake of approximately 51% in Option Care Health, while McKesson will invest approximately $1.4 billion for a minority interest of approximately 49%. Option Care Health will continue to operate as a separate company under its existing management team. Following the closing of the transaction, McKesson intends to account for its minority interest using the equity method of accounting, recording its share of Option Care Health's net income or loss in Other Income, net.

CVS Health raised its full-year outlook for its Health Care Benefits segment after stronger underlying performance in the first half of the year, now expecting adjusted operating income of $5.03-$5.37 billion, more than $1 billion above its earlier guidance. The company guided to a full-year medical benefit ratio of 89.8%, plus or minus 25 basis points, saying the forecast takes a prudent view of second-half medical cost trends. Health Care Benefits revenues rose more than 3% year over year to above $37 billion in the second quarter of 2026, helped by strength in the Government business, while medical membership stood at approximately 26 million, unchanged sequentially but down about 700,000 from the prior-year quarter, largely reflecting CVS Health's exit from the Individual exchange business. Adjusted operating income for the segment was approximately $2.4 billion and the MBR was 87.4%, both meaningfully improved year over year, with changes in the individual exchange risk adjustment position related to the 2025 plan year and favorable prior-year development together contributing approximately $500 million, or 140 bps, to the quarter's MBR. Separately, Cardinal Health entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health through June 30, 2032, reaffirming its fiscal 2027 non-GAAP earnings per share growth guidance of 13% to 15%, or $12.40 to $12.60, and its long-term non-GAAP EPS growth outlook of 12% to 14%.

Google announced a major long-term power agreement with Constellation Energy, under which it will buy power tied to 890 megawatts of new nuclear capacity alongside a separate 2,700-megawatt supply agreement, supporting more than $4.3 billion in new Constellation investment. Constellation Energy shares jumped more than 6% premarket on the news, while Alphabet rose about 0.5%. Separately, Option Care Health shares surged more than 20% following a Financial Times report that McKesson and private equity firm Clayton Dubilier & Rice are in advanced talks to jointly acquire the infusion services provider in a transaction valued at more than $5 billion; McKesson stock is up 1.5%. Berkshire Hathaway disclosed in a regulatory filing that it purchased about 2.4 million shares of Lennar, sending Lennar up 1.5%. NeoGenomics rose 5% after announcing that current President and COO Warren Stone will take the helm from Tony Cook in January 2027, and reporting preliminary third-quarter total revenue of $209 million, topping the $205.9 million consensus estimate, per FactSet. Advanced Micro Devices rose nearly 2% after Citi raised its price target to $800, citing greater CPU demand driven by Meta's Muse AI agent, while Procter & Gamble rose 1.2% on an Evercore ISI upgrade to outperform and a price target increase to $166 from $161, and Corteva rose nearly 3% after JPMorgan upgraded the stock to overweight from neutral with a $19 price target.

Option Care Health shares surged 22% in after-hours trading on Monday after the Financial Times reported that McKesson and private equity firm Clayton Dubilier & Rice are in advanced talks to acquire the infusion services provider in a deal expected to value the company at more than $5 billion including debt. Under the proposed terms, CD&R would take a 51% controlling stake in Option Care, while McKesson would hold the remaining 49%, with a provision granting McKesson the right to purchase the buyout firm's stake in the future. Citing people familiar with the matter, the report said an agreement could be reached as soon as Tuesday, though negotiations are ongoing and could still fall apart. Before Monday's after-hours spike, Option Care shares had fallen 27% year-to-date, leaving the company with an enterprise value of roughly $4.6 billion, including a $1.2 billion debt load. Option Care Health is the largest independent provider of medical infusion services in the U.S., serving over 315,000 patients nationwide last year through at-home services and 184 dedicated care centers.

Alignment Healthcare announced that its Alignment Health Plan will add Hoag, a large Orange County health system, to its network for Medicare members starting January 1, 2027. The agreement comes as Alignment Healthcare's share price sits under pressure, with the stock down 41.36% on a 30 day share price return basis and 60.73% year to date, while the 3 year total shareholder return remains positive at 8.47% and the 1 year total shareholder return has declined 52.23%. Analysts following the company see a wide gap between their narrative fair value of about $22.23 and the last close at $7.94, with 14 investors viewing Alignment Healthcare as 64% undervalued. On simple P/E math the stock screens as expensive, trading at about 40.5x earnings versus 24.3x for the wider US Healthcare industry and roughly 34.5x for peers, even though the fair ratio is estimated at 43x. The bull case rests on a technology-enabled care model, administrative automation and expansion into existing counties and new states, but it depends on stable Medicare Advantage funding and clean accounting, and any adverse regulatory or legal outcome could quickly challenge those assumptions.

Hims & Hers Health, Inc. announced the appointment of two new clinical experts to its global medical leadership team, naming Kultar Garcha, MD, as Chief Medical Officer of the UK and EMEA and Matt Vickers, FRACGP, MBBS, BMedSci, AICGG, as Chief Medical Officer of Hims Australia. The two appointments are the company's latest step in strengthening the local clinical leadership that underpins its international growth, and both executives will report into a global medical leadership structure led by Global Chief Medical Officer Pat Carroll, MD. Dr. Garcha brings over two decades of experience across public and private UK and international health systems, including clinical leadership roles at Flow Neuroscience and Babylon Health and almost 15 years as a practicing NHS GP, and will oversee clinical quality, patient safety, and prescribing standards across the UK and EMEA. Dr. Vickers is a practicing GP and supervisor with more than a decade of experience in family medical practice and has led health-tech efforts at Eucalyptus since 2019, and as Chief Medical Officer he will lead clinical strategy in Australia as Hims & Hers deepens its presence in the region. The pair join an international medical leadership bench that includes Sandy Van, MD, CCFP, ABOM Dipl, who has served as Chief Medical Officer of Hims & Hers Canada since December 2025.

The Cigna Group introduced a new "Lead to One" vision at its 2026 Investor Day, aimed at driving durable growth through leadership in complex care and differentiated capabilities. The company reaffirmed its 2026 full-year financial guidance, including consolidated adjusted revenues of approximately $280 billion, consolidated adjusted EPS of at least $30.45, Evernorth Health Services pre-tax adjusted income from operations of at least $6.90 billion, Cigna Healthcare pre-tax adjusted income from operations of at least $4.55 billion, and a medical care ratio of 83.7% to 84.7%. Cigna also set long-term financial targets through 2030 of 10-14% adjusted EPS CAGR and approximately $50 billion in cumulative operating cash flow. As part of the plan, the company announced a new $3 billion multi-year modernization and productivity initiative to support growth and financial performance. Additionally, The Cigna Group Foundation is launching a new $10.5 million, three-year grant program to expand community support for patients and caregivers.

Labcorp Holdings is expanding in high-growth specialty testing markets while broadening its consumer testing business, with acquisitions, health-system relationships and new contracts boosting its reach. In the second quarter of 2026, the company completed acquisitions of select Parkview Health outreach laboratory services and Tribal Diagnostics, invested $225.7 million in acquisitions, and secured another Department of Defense contract to provide testing across military hospitals worldwide; net acquisitions added 1.2% to enterprise revenue growth and 1.9% to Diagnostics growth during the quarter. Enterprise adjusted operating margin expanded 70 basis points year over year to 15.8% in the second quarter of 2026, with Diagnostics margin up 50 basis points to 18% and BLS margin up 130 basis points to 17%. Management estimated that Affordable Care Act-related changes reduced second-quarter 2026 diagnostic volume by 20-30 basis points and continues to assume a 30-basis-point full-year impact, though the affected payer group represents less than 4-5% of diagnostic volume. Over the past 30 days, the Zacks Consensus Estimate for Labcorp's 2026 earnings per share has edged up 0.2% to $18.32, while the 2026 revenue consensus stands at $14.75 billion, implying 5.7% growth over 2025.

NewGenIvf Group Limited announced the pricing of a reasonable best efforts public offering expected to raise gross proceeds of approximately $1.25 million before deducting placement agent fees and other offering expenses. The offering consists of 17,857,143 Ordinary Shares or Pre-Funded Warrants in lieu thereof, priced at $0.07 per Common Share, or $0.06999 for each Pre-Funded Warrant, which equals the public offering price per Ordinary Share minus an exercise price of $0.00001 per Pre-Funded Warrant. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full, with the number of Ordinary Shares in the offering decreased on a one-for-one basis for each Pre-Funded Warrant sold. The transaction is expected to close on or about September 30, 2026, subject to customary closing conditions, and the Company expects to use the net proceeds together with existing cash for investment in K25.ai, restructuring of debt securities, working capital including manufacturing and deployment of Nodexus machines in the cell-sorting business, and general corporate purposes. Aegis Capital Corp. is acting as exclusive placement agent, Han Kun Law Offices LLP is acting as U.S. counsel to the Company, and Kaufman & Canoles, P.C. is acting as U.S. counsel to Aegis Capital Corp. A registration statement on Form F-1 previously filed with the SEC on August 20, 2026 was declared effective on September 28, 2026.

CorVel Corporation announced on September 22 that insurance carriers running Guidewire's ClaimCenter can now start and manage CorVel's managed care services directly from their claims screen, letting handlers pass injury details across with a single sign-on and receive status updates and recommendations without retyping. Ron Wojciechowski, CorVel's Senior Vice President of Payer Technical Solutions, pitched the integration as lowering the barrier to becoming a CorVel client, and the connection follows Guidewire's own standards and can be picked up through the Guidewire Marketplace. The launch follows CorVel's August 5 report of revenue of $260 million for the quarter ended June 30, up 11% from $235 million a year earlier, with gross profit up 19% to $67.8 million and earnings per share of $0.63 versus $0.52. CorVel ended the quarter with $256 million in cash and no borrowings, even after buying back $21.8 million of its stock. The announcement named no carriers that have adopted the tool and put no dollar figure on what it might add, while short interest sits at 11.58% of the float, reflecting skepticism over whether gross margins can sustain their current trajectory.

Aetna, a CVS Health company, is expanding its bundled prior authorization program across all cancer types for members in eligible Medicaid states as of September 1, with plans to extend it across all lines of business in 2027. The expansion builds on an initial roll-out in which almost 25% of eligible members received a bundled prior authorization, assuring their services were approved in advance. Aetna found that providers were submitting four separate prior authorizations on average for each member needing cancer treatment, and the bundles combine medical oncology, including chemotherapy and immunotherapy where appropriate, and radiation oncology services with associated high-tech imaging such as MRI or CT scans into a single request through one portal. Katerina Guerraz, Aetna Chief Operating Officer and President of Medicaid, said approving a broader set of treatments and related services upfront removes barriers that can delay care. According to the latest Aetna Provider Survey, 74% of providers identified administrative burden as the top challenge facing clinical staff, and nearly one-third, or 31%, cited prior authorization management as the single largest contributor; 30% of respondents believed they could save more than an hour and 80% expect to save more than 30 minutes daily through technology solutions such as bundles. Aetna expects to expand eligibility to Medicare and Commercial members in the first half of 2027.

CorVel Corporation has launched its CareMC Accelerator for Guidewire ClaimCenter, letting insurers initiate and manage Managed Care services directly within the claims workflow through secure Single Sign-On and structured data exchange. The integration embeds managed care as a coordinated part of claims handling, which could reduce administrative friction while giving claims teams real-time visibility into care activity and outcomes. CorVel's investment narrative centers on a specialized healthcare services company that leans heavily on technology to keep claims and managed care tightly coordinated while steadily returning capital through ongoing buybacks, and the new product fits that tech-first story by potentially reinforcing near-term catalysts around product adoption and deepening customer stickiness. Even so, the launch on its own may not be a dramatic financial swing factor right away, and it slightly raises the stakes around technology execution risk and integration quality. The article also flags insider selling as a key concern investors should not overlook.

Addus HomeCare agreed on September 14 to acquire the personal care division of AccentCare for an anticipated $275 million, a deal expected to add roughly $280 million in annualized revenue, nearly a fifth of the company's current revenue base. The AccentCare operations serve an average daily census of about 13,700 customers across a 10-state footprint, deepening Addus in Texas, Illinois, California, and Arizona while adding a foothold in Colorado, Georgia, Minnesota, Pennsylvania, Tennessee, and Washington. The purchase covers only personal care, leaving AccentCare's hospice and home health operations out of the deal, and will be funded through Addus's revolver and cash on hand rather than new share issuance. The transaction has not closed and still requires regulatory approval and customary closing conditions. The deal follows Addus's second-quarter results, reported August 3, when net service revenues rose 8.0% to $377.4 million and adjusted EBITDA climbed 11.9% to $49.2 million, with personal care up 6.8% organically and hospice up 11.1% organically. Addus carried $64.3 million in debt and generated $40.0 million in quarterly operating cash flow ahead of the acquisition.